Prevalence of Cancer in Membranous Nephropathy: A Systematic Review and Meta-Analysis of Observational Studies

Napat Leeaphorn\textsuperscript{a} Pogsathorn Kue-A-Pai\textsuperscript{a} Natanong Thamcharoen\textsuperscript{a} Patompong Ungprasert\textsuperscript{c} Michael B. Stokes\textsuperscript{b} Eric L. Knight\textsuperscript{a}

\textsuperscript{a}Department of Internal Medicine, Bassett Medical Center and Columbia University College of Physicians and Surgeons, Cooperstown, N.Y., and \textsuperscript{b}Department of Pathology, Columbia University College of Physicians and Surgeons, New York, N.Y., USA; \textsuperscript{c}Division of Rheumatology, Department of Medicine, Siriraj Hospital, Faculty of Medicine, Mahidol University, Bangkok, Thailand

\section*{Key Words}
Cancer · Epidemiology · Membranous nephropathy · Nephrotic syndrome · Phospholipase A\textsubscript{2} receptor

\section*{Abstract}
\textbf{Background:} The association between membranous nephropathy (MN) and cancer has been well documented. However, the true prevalence and characteristics of cancer associated with MN have not been well described. \textbf{Methods:} A systematic review and meta-analysis of cohort studies was conducted to summarize the prevalence of cancer-associated MN as well as patient characteristics and types of cancer in this population. We used a random-effects meta-analysis model to estimate the prevalence of cancer. \textbf{Results:} We included 6 studies (n = 785). The estimated prevalence of cancer was 10.0\% (95\% CI, 6.1–14.6). The mean age of MN patients with cancer was 67 ± 7 years. The diagnosis of cancer preceded the diagnosis of MN in 20 ± 6.8\%. Lung cancer was the most common type of tumor, accounting for 22 cases (26\%), followed by prostate cancer (13 cases, 15\%), hematologic malignancies (12 cases, 14\%), colorectal cancer (9 cases, 11\%), breast cancer (6 cases, 7\%), and stomach and esophageal cancer (5 cases, 6\%). \textbf{Conclusion:} The estimated prevalence of cancer in patients with MN is 10\% (95\% CI, 6.1–14.6). The vast majority of tumors associated with MN are lung and prostate cancer. Hematologic malignancies should also be considered as one of the potential cancers associated with MN. Our study was based on a largely Caucasian population; therefore, the findings might not be applicable to other populations.

\section*{Introduction}
Membranous nephropathy (MN) is a pathologic entity characterized by diffuse thickening of the glomerular basement membrane observed by light microscopy \cite{1}. MN was historically considered the most common nephrotic syndrome in adults, but recent literature suggests that focal segmental glomerulosclerosis is now the leading cause of nephrotic syndrome \cite{2}. Approximately 75\% of the cases of MN are idiopathic, whereas the remainder are associated with infections, malignancies, autoimmune diseases and drug toxicity \cite{1}.  

\textsuperscript{1} Dr. Napat Leeaphorn  
Department of Internal Medicine, Bassett Medical Center and Columbia University College of Physicians and Surgeons  
1 Atwell Road, Cooperstown, NY 13326 (USA)  
E-Mail napat.leeaphorn@bassett.org

\textsuperscript{2} \copyright 2014 S. Karger AG, Basel
The association between MN and cancer has been well recognized since 1966 when Lee et al. [3] reported that 11% of patients with nephrotic syndrome had carcinoma. However, the true prevalence of cancer in patients with MN remains unknown and has been variously estimated as ranging between 5 and 22% [4–9]. Traditionally, the solid organ cancers most commonly associated with MN have been lung and gastrointestinal cancers [10], whereas MN associated with hematologic malignancy has been considered a rare entity [11].

The prevalence of cancer-associated MN varies across studies, in part due to variation in patient selection, follow-up periods, and different biopsy policies among centers. Furthermore, most studies to date have been limited in size given that MN is a relatively rare disease. Although several reviews have addressed the relationship between MN and the occurrence of cancer, to the best of our knowledge, no meta-analysis has been conducted to examine this relationship. We conducted a systematic review and meta-analysis to evaluate the prevalence of cancer in MN patients and the types of cancer associated with MN by reviewing existing observational study data.

Materials and Methods

Data Sources and Searches
The protocol for this review was developed according to standard reporting guidelines [12, 13]. We conducted MEDLINE and Cochrane database searches of English-language studies undertaken in human subjects aged 18 or older using the following items: ‘cancer AND glomerulopathy’, ‘cancer AND glomerular disease’, ‘cancer AND nephrotic syndrome’, ‘cancer AND membranous nephropathy’, ‘membranous nephropathy AND epidemiology’. The resulting publications identified with this search strategy as of February 7, 2014 were examined. We did not include articles based on hand searches of bibliographies, Internet searches or unpublished studies in the form of posters or abstracts in our search strategy.

Study Selection and Data Extraction
Studies pertaining to the determination of cancer risk in patients with MN were included for analyses if the following criteria were met: (1) they were cohort studies of patients with MN including prospective and/or retrospective studies and (2) data on cancer prevalence were demonstrated. Case reports, case series, cross-sectional studies, studies with uncertain follow-up adherence, studies that limited the population age, studies that did not specify the types of tumor, and studies that demonstrated incidence of cancer only after the time of diagnosis of MN (not prior to the diagnosis of MN) were excluded from our analyses. All identified abstracts were reviewed independently by 2 investigators (N.L. and P.U.). The quality of each study was independently evaluated by each investigator using the Newcastle-Ottawa quality assessment scale [14]. Discrepancies in data extraction and quality assessment were resolved through collateral discussion. For this study, we extracted the following variables: author’s name(s), publication year, country where the study was conducted, period of follow-up, number of patients studied, number of cancers observed in the cohort, patients’ age and gender, and the presence of cancer symptoms at the time of diagnosis of MN. We contacted the authors of the primary reports to request any unpublished data. If the authors did not reply, we used the available data for our analyses.

Data Synthesis and Analysis
The characteristics of MN patients with cancer enrolled in the study were reported as frequencies or mean ± standard deviation. The prevalence of cancer and 95% CIs were reported using a Der-Simonian-Laird random-effects model with double arcsine transformation [15, 16]. We ran a random-effect model rather than a fixed-effects model because of the high likelihood of heterogeneity between study variance. The heterogeneity of effect size estimates across studies was described with the I² index and Q statistic’s p value [17]. Analyses were performed using MetaXL software (http://www.epigear.com). The frequencies of each type of cancer were presented as a crude percentage.

Results

Description of Included Studies
The initial search yielded 2,482 articles (fig. 1). Of these, 2,379 were deemed ineligible because they were not related to the study question. We reviewed the full text of the remaining 35 articles for possible inclusion. A total of 13 studies were potentially eligible based on our inclusion criteria. Of these, 3 studies were excluded because of lack of follow-up data [18–20], 1 study did not report the total number of MN patients in the study [3], 1 study was based on MN patients aged 60 or over, so it did not represent the general MN population [7], 1 study did not specify the types of tumor that MN patients had [6], and 1 study described the incidence of cancers only after the diagnosis of MN was made [21]. Eventually, 6 cohort studies were included in the meta-analysis [4–6, 8, 9, 22]. The characteristics of these studies are outlined in table 1. A total of 785 patients with MN were represented in these studies.

Cancer Prevalence
The prevalence of cancers within the 6 individual study populations ranged between 4.8 and 20.4% (crude unweighted mean 10.8%), with an overall meta-analytical prevalence of 10.0% (95% CI, 6.1–14.6), and there was evidence of a moderate level of heterogeneity (I² = 73.8%, p < 0.001; fig. 2).

Reporting Bias
A funnel plot was not drawn because of the limited number of studies. As a rule of thumb, tests for funnel
Search results
MEDLINE: n = 2,414
Cochrane: n = 68

Excluded: n = 2,447
(outcomes or populations irrelevant
to this review, review articles)

Full text analysis: n = 35

Excluded: n = 7
3 studies were excluded due to lack of follow-up data
1 study was excluded because a total number of
MN patients was not reported
1 study was excluded because it only included
elderly patients
1 study was excluded because types of cancers
were not specified
1 study was excluded because it described the
incidence of cancer only after the diagnosis of MN
was made

Total number of studies
included in final review: n = 6
(785 patients)

Table 1. Characteristics of cohort studies of cancer prevalence in patients with MN in the meta-analysis

<table>
<thead>
<tr>
<th>Country</th>
<th>Study design</th>
<th>Follow-up period</th>
<th>Mean follow-up, years</th>
<th>Gender, % male</th>
<th>Mean age, years</th>
<th>Patients with MN, n</th>
<th>Cancer, n</th>
<th>Prevalence of cancer, %</th>
<th>Mean age at the time of cancer diagnosis, years</th>
<th>Gender of cancer patients, % male</th>
<th>Cancer patients with age ≥65, %</th>
<th>Diagnosed with cancer before the diagnosis of MN, %</th>
<th>Diagnosed with cancer at the time of or following the diagnosis of MN, %</th>
<th>Quality assessment (Newcastle-Ottawa scale)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Country UK France USA Czech Republic France Norway
Study design prospective cohort prospective cohort retrospective cohort retrospective cohort retrospective cohort retrospective population-based cohort
Mean follow-up, years 3.4 NA NA 2 NA NA
Gender, % male 59 63.1 NA NA NA 64
Mean age, years 38.2 44.8 NA NA NA 53.5
Patients with MN, n 66 82 107 129 240 161
Cancer, n 7 4 9 8 24 33
Prevalence of cancer, % 10.6 4.8 10.3 6.2 10 20.49
Mean age at the time of cancer diagnosis, years 47.64 61 63.8 63 73 67.66
Gender of cancer patients, % male 71.42 100 63.8 63 73 66.67
Cancer patients with age ≥65, % 0 50 55.55 50 75 63.63
Diagnosed with cancer before the diagnosis of MN, % 14.28 25 22.22 12.5 12.5 27.27
Diagnosed with cancer at the time of or following the diagnosis of MN, % 85.72 75 77.78 87.5 87.5 72.72
Quality assessment (Newcastle-Ottawa scale)
Selection 3 stars 3 stars 3 stars 3 stars 3 stars 3 stars
Comparability 1 star 1 star 1 star 1 star 1 star 1 star
Outcome 3 stars 2 stars 2 stars 2 stars 2 stars 3 stars

NA = Not available.
plot asymmetry should be used only when there are at least ten study groups. With fewer studies, the power of the test is too low to distinguish chance from real asymmetry [23].

Baseline Characteristics of Cancer-Associated MN

Patients tended to present in their sixth to seventh decade with the mean age being 66 ± 7 years. Males represented up to 66% of all cancer patients with MN. Of all the cases of cancer associated with MN in all the studies combined, the cancer was discovered before the diagnosis of MN in only 20 ± 6.8%. For the remaining 80 ± 15%, the cancer was diagnosed at the time of or following the diagnosis of MN.

Types of Cancer Associated with MN

The vast majority of tumors associated with MN were solid tumors (73 cases, 86%). Lung cancer was the most common type of solid tumor accounting for 26% (22 cases) followed by prostate cancer (13 cases, 15%), colorectal cancer (9 cases, 11%), breast cancer (6 cases, 7%), stomach and esophageal cancer (5 cases, 6%), bladder cancer (4 cases, 5%), cervical and uterine cancer (3 cases, 4%) and renal cell carcinoma (2 cases, 2%; table 2).

Out of 85 cases of cancer with MN, there were 12 cases (14%) of hematologic malignancies. It could be noted that when all types of hematologic malignancies were combined, it became the third most common type of cancer after lung and prostate cancer. Lymphoma was the most common type of hematologic malignancy (6 cases; 3 cases of non-Hodgkin’s lymphoma, 1 case of Hodgkin’s lymphoma, and 2 cases that were unspecified), followed by chronic lymphocytic leukemia (4 cases), chronic myelogenous leukemia (1 case) and polycythemia vera (1 case).

Discussion

This study presents, to our knowledge, the first systematic review and meta-analysis of cancer prevalence in patients with MN. We confirmed a close association between MN and cancer with a prevalence rate of 10% (95% CI, 6.1–14.6). It should be noted that we did not take standardized incidence ratio into account for the analyses because there were only 2 cohort studies that reported this [8, 9]. Standardized incidence ratio would have been a better statistical tool to compare the incidence rate of cancer in MN patients with that in the general population.

Heterogeneity between studies was present in this meta-analysis. We suspect that the difference in follow-up periods was the main source of heterogeneity, as half of the studies did not report the mean length of follow-up, and the mean follow-up also varied between 2 and 6.2 years in the remaining studies. Theoretically, the longer the follow-up period the higher the number of cancer cases that would be reported, as evident by the work of Bjørneklett et al. [9], who stated that the risk of develop-
ing cancer persisted for at least 5 years after the diagnosis of MN [9]. In addition, methodological differences in cancer detection might also play a role in the heterogeneity in our study. Bjørneklett et al. [9] identified cancer in patients with MN by using record linkage with national cancer registries, whereas other studies identified cancer by accessing patient charts from their own institutions. The biopsy practices and policies among centers might also cause variation in cancer prevalence as some nephrologists might be reluctant to perform a kidney biopsy in patients with symptomatic cancer as the biopsy results would not be likely to change the management.

Not surprisingly, the incidence of cancer associated with MN increases with age [7, 21]. Lefaucheur et al. [8] reported that the frequency of cancer was up to 20–25% after age 60 years. In our analyses, the mean age of MN patients with cancer was 66.35 ± 6.75 years. Interestingly, only 20 ± 6.8% of MN patients had the diagnosis of cancer before the diagnosis of MN. Cancer was discovered at the time of or following the diagnosis of MN in the remainder. This finding is important because it emphasizes the benefit of cancer screening in patients with newly diagnosed MN. There are, however, two shortcomings worth mentioning because of insufficient data. First, we were unable to further subdivide the proportions of patients whose cancer was discovered concomitantly with the diagnosis of MN or during the follow-up period. Secondly, it would have been even more interesting clinically if it were possible to learn the percentage of patients who already had cancer-related symptoms at the time of renal biopsy. Lefaucheur et al. [8] reported that 52% of all patients with cancer-associated MN who did not have the diagnosis of cancer at the time of renal biopsy had cancer-related symptoms such as cough, urinary retention, and impairment of general health status. Unfortunately, the remaining 5 studies did not mention cancer-related symptoms. None of the studies mentioned the rate of thromboembolic events. Lefaucheur et al. [8] and Bjørneklett et al. [9] demonstrated no association between the development of cancer and the degree of proteinuria, serum albumin or other laboratory parameters.

In our study, we did not have enough data to analyze the median time from diagnosis of MN to cancer in MN patients in whom cancer was discovered during the follow-up period. However, Bjørneklett et al. [9] reported that the median time was 5 years, which suggests that the predilection for cancer in participants with MN persists for many years. Therefore, close follow-up is necessary if cancer is not detected on initial screening.

It has been well documented in the literature that MN is closely associated with solid tumors rather than with hematologic malignancies. In our analyses, lung cancer

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung</td>
<td>6 (18.18)</td>
<td>8 (33.33)</td>
<td>3 (37.5)</td>
<td>2 (22.22)</td>
<td>1 (25)</td>
<td>2 (28.57)</td>
<td>22 (25.88)</td>
</tr>
<tr>
<td>Prostate</td>
<td>7 (21.21)</td>
<td>5 (20.83)</td>
<td>1 (12.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>13 (15.29)</td>
</tr>
<tr>
<td>Hematologic</td>
<td>5 (15.15)</td>
<td>2 (8.33)</td>
<td>0 (0)</td>
<td>2 (22.22)</td>
<td>1 (25)</td>
<td>2 (28.57)</td>
<td>12 (14.11)</td>
</tr>
<tr>
<td>Colon/rectal</td>
<td>4 (12.12)</td>
<td>1 (4.16)</td>
<td>1 (12.5)</td>
<td>1 (11.11)</td>
<td>0 (0)</td>
<td>2 (28.57)</td>
<td>9 (10.58)</td>
</tr>
<tr>
<td>Breast</td>
<td>4 (12.12)</td>
<td>1 (4.16)</td>
<td>0 (0)</td>
<td>1 (11.11)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>6 (7)</td>
</tr>
<tr>
<td>Stomach/esophagus</td>
<td>1 (3)</td>
<td>2 (8.33)</td>
<td>0 (0)</td>
<td>1 (11.11)</td>
<td>1 (25)</td>
<td>0 (0)</td>
<td>5 (8.1)</td>
</tr>
<tr>
<td>Bladder</td>
<td>2 (6)</td>
<td>1 (4.16)</td>
<td>0 (0)</td>
<td>1 (11.11)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>4 (4.7)</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (11.11)</td>
<td>1 (25)</td>
<td>0 (0)</td>
<td>2 (2.35)</td>
</tr>
<tr>
<td>Larynx</td>
<td>0 (0)</td>
<td>1 (4.16)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (1.17)</td>
</tr>
<tr>
<td>Thymus</td>
<td>0 (0)</td>
<td>1 (4.16)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (1.17)</td>
</tr>
<tr>
<td>Mediastinum</td>
<td>0 (0)</td>
<td>1 (4.16)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (1.17)</td>
</tr>
<tr>
<td>Cervix/uterus</td>
<td>1 (3)</td>
<td>1 (4.16)</td>
<td>1 (12.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>3 (3.5)</td>
</tr>
<tr>
<td>Hepatocellular</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (12.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (1.17)</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (12.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (1.17)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>1 (3)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (1.17)</td>
</tr>
<tr>
<td>Skin, nonmelanoma</td>
<td>1 (3)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (1.17)</td>
</tr>
<tr>
<td>Disseminated, unknown</td>
<td>1 (3)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (1.17)</td>
</tr>
<tr>
<td>Wilms’ tumor</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (1.17)</td>
</tr>
</tbody>
</table>

Values are number of cases (percentage). Number and percent of cases (in parentheses).
was the most common solid tumor, accounting for almost a quarter of all cancer patients, followed by prostate cancer, colorectal cancer, breast cancer and stomach and esophageal cancer, respectively. It is probably worth noting that the high frequency of prostate cancer was overwhelmingly reported from the 2 most recent studies [8, 9]. This finding may be explained by a better detection of this slow-growing tumor by prostate-specific antigen testing and modern imaging [24].

Interestingly, we found that the frequency of hematologic malignancies was also high, the third rank after lung and prostate cancer. Lymphoma (6 cases) was the most common hematologic malignancy associated with MN followed by chronic lymphocytic leukemia (4 cases). To date, MN associated with hematologic malignancies has only been described in isolated case reports [11, 25]. Our findings suggest that the clinicians should be more vigilant searching for hematologic malignancies.

The precise pathogenic mechanism whereby cancer might be associated with MN has yet to be elucidated. Beck [26] proposed four potential mechanisms: (1) antibodies may be created against a tumor antigen immunologically similar to an endogenous podocyte antigen, thereby leading to in situ immune complex formation; (2) shed tumor antigens may form circulating immune complexes that are subsequently trapped in the glomerular capillary wall; (3) circulating antibodies may also react to the tumor antigens that have already been planted in the subepithelial location, or (4) an extrinsic process such as viral infection or an underlying abnormal immune response may be responsible for both cancer and MN.

Since the discovery of the transmembrane glycoprotein M-type phospholipase A2 receptor (PLA2R), which was identified as the major target podocyte antigen involved in the majority of adult idiopathic MN cases [24], a distinction between idiopathic and secondary MN can be made more precisely by the detection of circulating antibodies against PLA2R. The patients with MN who have detectable anti-PLA2R are unlikely to have associated malignancy, whereas the absence of anti-PLA2R increases the risk of malignancy-associated MN and warrants careful searches for cancer [27]. Note that an anti-PLA2R autoantibody assay has not been approved by the US Food and Drug Administration at the time of this writing, although it is available in Europe [28]. Glomerular pathologic findings are also very useful. Strong immunofluorescence staining of glomerular PLA2R IgG1 and IgG2 is frequently seen with cancer-associated MN, whereas the dominance of deposits of IgG4 generally favors idiopathic MN [29, 30]. However, Larsen et al. [31] did find positive staining with IgG4 predominance in 3 out of 12 patients (25%) who had malignancy-associated MN. The question remains whether these patients had coincidental/unrelated malignancies that were detected after the diagnosis of primary MN. In addition to the above, the presence of more than eight inflammatory cells infiltrating the glomeruli seems to strongly increase the likelihood of cancer in patients with MN [8].

It has now become standard practice to search for malignancy in older patients with newly diagnosed MN once other secondary causes have been excluded. However, there is no consensus on how aggressive clinicians should be in search of occult malignancy. Recent literature based on expert opinion suggests vigorous pursuit for cancer if circulating anti-PLA2R autoantibodies are undetected and/or IgG deposits are not IgG4 subclass-dominant and/or there are more than eight inflammatory cells infiltrating the glomeruli [1, 32, 33]. Based on our results showing a relatively high prevalence of cancer in the MN population, especially in older patients, we concur with this approach. If cancer is not detected on initial screening, these patients should have close medical follow-up because of the long-term risk of cancer occurrence.

Our analysis should be interpreted with caution. First, the observational studies were moderately heterogeneous and thus publication bias and a residual confounding bias may have existed although we cannot assess these hypotheses. Secondly, overall numbers of patients in each study and overall were relatively small, and long-term follow-up was variable. Thirdly, all of the studies included were conducted in developed Western countries with the majority of the subjects being Caucasian, therefore our findings may not represent MN populations from other parts of the world. Lastly, we could not judge whether the occurrence of cancer in this study was a causative factor for developing MN or a mere coincidence. Given that MN populations were likely to be elderly patients who were already at high risk for developing cancer, it is possible that some of the cancer cases in the study were just coincidental.

In conclusion, the results of our meta-analysis confirm a high prevalence of cancer in the MN population. The malignancies most frequently associated with MN are lung and prostate cancer, followed by colorectal cancer, breast cancer and lymphoma. Further study is warranted to determine the true incidence of cancer in MN patients with negative anti-PLA2R autoantibodies and/or the absence of IgG4 subclass dominance by immunofluorescence and/or the presence of more than eight inflamma-
tory cells. Until such information is available, it is reasonable to pursue aggressive cancer screening in patients with these serologic and glomerular morphologic pictures. Systematic investigation for possible lung and prostate cancer should be the first priority. Hematologic malignancies should also be considered as a potential cause of MN.

Disclosure Statement

The authors declare that they have no financial conflict of interest related to this study.